137 related articles for article (PubMed ID: 8296900)
1. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients.
Bradwejn J; Koszycki D
Am J Psychiatry; 1994 Feb; 151(2):261-3. PubMed ID: 8296900
[TBL] [Abstract][Full Text] [Related]
2. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder.
Bradwejn J; Koszycki D; Couëtoux du Tertre A; van Megen H; den Boer J; Westenberg H
Arch Gen Psychiatry; 1994 Jun; 51(6):486-93. PubMed ID: 8192551
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity to cholecystokinin-tetrapeptide in major depression.
Koszycki D; Copen J; Bradwejn J
J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943
[TBL] [Abstract][Full Text] [Related]
4. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder.
Ströhle A; Kellner M; Holsboer F; Wiedemann K
Am J Psychiatry; 2001 Sep; 158(9):1514-6. PubMed ID: 11532742
[TBL] [Abstract][Full Text] [Related]
5. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings.
Bradwejn J; Koszycki D; Payeur R; Bourin M; Borthwick H
Am J Psychiatry; 1992 Jul; 149(7):962-4. PubMed ID: 1609879
[TBL] [Abstract][Full Text] [Related]
6. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.
Maron E; Tõru I; Vasar V; Shlik J
J Psychopharmacol; 2004 Jun; 18(2):194-9. PubMed ID: 15260907
[TBL] [Abstract][Full Text] [Related]
7. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
Bradwejn J; Koszycki D; Bourin M
J Psychiatry Neurosci; 1991 Jul; 16(2):91-5. PubMed ID: 1911739
[TBL] [Abstract][Full Text] [Related]
8. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
Plag J; Gaudlitz K; Zschucke E; Yassouridis A; Pyrkosch L; Wittmann A; Holsboer F; Ströhle A
Curr Pharm Des; 2012; 18(35):5619-26. PubMed ID: 22632477
[TBL] [Abstract][Full Text] [Related]
9. Neurobiological investigations into the role of cholecystokinin in panic disorder.
Bradwejn J
J Psychiatry Neurosci; 1993 Jul; 18(4):178-88. PubMed ID: 8104032
[TBL] [Abstract][Full Text] [Related]
10. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers.
Koszycki D; Cox BJ; Bradwejn J
Am J Psychiatry; 1993 Dec; 150(12):1881-3. PubMed ID: 8238648
[TBL] [Abstract][Full Text] [Related]
11. The acute antipanic activity of aerobic exercise.
Ströhle A; Feller C; Onken M; Godemann F; Heinz A; Dimeo F
Am J Psychiatry; 2005 Dec; 162(12):2376-8. PubMed ID: 16330604
[TBL] [Abstract][Full Text] [Related]
12. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms.
Le Mellédo JM; Bradwejn J; Koszycki D; Bichet DG; Bellavance F
Biol Psychiatry; 1998 Sep; 44(5):364-6. PubMed ID: 9755359
[TBL] [Abstract][Full Text] [Related]
13. Effect of aging on cholecystokinin-induced panic.
Flint AJ; Koszycki D; Vaccarino FJ; Cadieux A; Boulenger JP; Bradwejn J
Am J Psychiatry; 1998 Feb; 155(2):283-5. PubMed ID: 9464213
[TBL] [Abstract][Full Text] [Related]
14. Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4).
Zwanzger P; Eser D; Völkel N; Baghai TC; Möller HJ; Rupprecht R; Padberg F
Int J Neuropsychopharmacol; 2007 Apr; 10(2):285-9. PubMed ID: 16817979
[TBL] [Abstract][Full Text] [Related]
15. Aging and panicogenic response to cholecystokinin tetrapeptide: an examination of the cholecystokinin system.
Flint A; Bradwejn J; Vaccarino F; Gutkowska J; Palmour R; Koszycki D
Neuropsychopharmacology; 2002 Oct; 27(4):663-71. PubMed ID: 12377403
[TBL] [Abstract][Full Text] [Related]
16. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings.
Wiedemann K; Jahn H; Yassouridis A; Kellner M
Arch Gen Psychiatry; 2001 Apr; 58(4):371-7. PubMed ID: 11296098
[TBL] [Abstract][Full Text] [Related]
17. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
[TBL] [Abstract][Full Text] [Related]
18. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
Bradwejn J; Koszycki D; Shriqui C
Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin and panic disorder--three unsettled questions.
Rehfeld JF
Regul Pept; 2000 Sep; 93(1-3):79-83. PubMed ID: 11033055
[TBL] [Abstract][Full Text] [Related]
20. Trait dissociation affects the behavioral response to cholecystokinin tetrapeptide in healthy man.
Kellner M; Yassouridis A; Hua Y; Wendrich M; Naber D; Wiedemann K
Psychiatry Res; 2002 Aug; 111(1):93-6. PubMed ID: 12140124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
